Author's response to reviews

Title: Promoter methylation of CDKN2A and the lack of p16 expression characterize patients with hepatocellular carcinoma

Authors:

Antal Csepregi (csepregia@yahoo.de)
Matthias PA Ebert (ebertm@gmx.de)
Christoph Röcken (croecken@path.uni-kiel.de)
Regine Schneider-Stock (regine.schneider-stock@med.ovgu.de)
Juliane Hoffmann (juliane.hoffmann@med.ovgu.de)
Hans-Ulrich Schulz (hans-ulrich.schulz@med.ovgu.de)
Albert Roessner (albert.roessner@med.ovgu.de)
Peter Malfertheiner (peter.malfertheiner@med.ovgu.de)

Version: 2 Date: 24 July 2009

Author's response to reviews: see over
To
Editorial Board
BMC Cancer

Title: Promoter Methylation of CDKN2A and the Lack of p16 Expression Characterize Patients With Hepatocellular Carcinoma.

Authors: Antal Csepregi, MD, PhD, Matthias P.A. Ebert, MD, Christoph Röcken, MD, Regine Schneider-Stock, PhD, Juliane Hoffmann, PhD, Hans-Ulrich Schulz, MD, Albert Roessner, MD, Peter Malfertheiner, MD

Dear Sir,

we consider to publish our experiences on changes of promoter methylation of the CDKN2A gene and expression of p16 protein in patients with liver tumors. We show that a methylated promoter of this gene in association with the lack of p16 expression characterizes patients with hepatocellular carcinoma. Our data also indicate that fibrotic changes of the liver seem to correlate with the induction of p16 expression.

The content of the manuscript is original and it has not been published or accepted for publication, either in whole or in part, in any form. No part of the manuscript is currently under consideration for publication elsewhere.

With kind regards,

Antal Csepregi, MD, PhD
Department of Medicine
Hufeland Klinikum GmbH Bad Langensalza
Rudolph-Weiss-Straße 1-5
D-99947 Bad Langensalza, Germany
Phone: (49)-3603-855-673
Fax: (49)-3603-855-390
E-mail: csepregia@yahoo.de